Nasdaq · CIK 0001690585
DNTH Dianthus Therapeutics, Inc. /DE/
Insider trading from SEC Form 4. Last filing 25 d ago. Close $82.37 on Oct 9, 2026, +150% from the 52-week low and -29% from the high.
In brief
Dianthus Therapeutics, Inc. /DE/ (DNTH) has 50 SEC Form 4 filings on file from 8 insiders, the latest filed on Sep 18, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 7 open-market sells worth $26M, net -$26M.
21 open-market trades have been scored at DNTH. The newest: Edward Carr (CHIEF ACCOUNTING OFFICER) sold $2.0M of stock on Sep 17, 2026, filed Sep 18, 2026, scored 25 (weak), under a 10b5-1 plan. The largest of the 21 shown: Marino Garcia (CEO AND PRESIDENT) sold $18M on Aug 7, 2026, scored 50 (moderate), under a 10b5-1 plan. 2 insiders sold within 14 days of each other around Sep 1, 2026.
21 Form 144 notices of planned sales are on file, the latest filed Sep 17, 2026.
Last 90 days
Net insider value
-$26M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
7
$26M by 6 insiders
Insiders on file
8
with a Form 4 at this company
Price and insider trades, last year
DNTHOct 9, 2026 · close 82.37
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Dianthus Therapeutics, Inc. /DE/, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Edward Carr CHIEF ACCOUNTING OFFICER sell | $2.0M 20,000 shares | -100% | - | |
| 33Weak | Simrat Randhawa EVP, Head of R&D sell | $2.5M 23,124 shares | -85% | +347% from low-8% from high | |
| 30Weak | Simon Read director sell | $327k 2,778 shares | -100% | +401% from low-2% from high | |
| 29Weak | Simon Read director sell | $304k 2,777 shares | -100% | +492% from low-1% from high | |
| 40Moderate | Adam M Veness SVP, General Counsel and Sec. sell | $2.2M 20,000 shares | -522% | +481% from low-3% from high | |
| 38Weak | Anne McGeorge director sell | $845k 7,750 shares | -100% | +492% from low-1% from high | |
| 50Moderate | Marino Garcia CEO AND PRESIDENT sell | $18M 166,000 shares | -72% | +481% from low-3% from high | |
| 32Weak | Ryan Savitz EVP, CFO & CBO sell | $3.2M 31,249 shares | -100% | +433% from low0% from high | |
| 25Weak | Adam M Veness SVP, General Counsel and Sec. sell | $2.4M 30,000 shares | -100% | +386% from low-14% from high | |
| 25Weak | Simrat Randhawa EVP, Head of R&D sell | $2.4M 26,530 shares | -87% | +431% from low-7% from high | |
| 7Weak | Paula Soteropoulos director sell | $51k 599 shares | -100% | +414% from low-9% from high | |
| 36Weak | Ryan Savitz EVP, CFO & CBO sell | $739k 8,224 shares | -100% | +488% from low0% from high | |
| 15Weak | Paula Soteropoulos director sell | $48k 599 shares | -100% | +465% from low-3% from high | |
| 40Moderate | Ryan Savitz EVP, CFO & CBO sell | $9.5M 114,367 shares | -100% | +465% from low-3% from high | |
| 40Moderate | Paula Soteropoulos director sell | $2.2M 27,594 shares | -100% | +429% from low-10% from high | |
| 40Moderate | Edward Carr CHIEF ACCOUNTING OFFICER sell | $3.6M 43,682 shares | -100% | +441% from low-8% from high | |
| 50Moderate | Marino Garcia CEO AND PRESIDENT sell | $10M 122,918 shares | -100% | +441% from low-8% from high | |
| 40Moderate | Simrat Randhawa EVP, Head of R&D sell | $2.8M 33,830 shares | -100% | +441% from low-8% from high | |
| 31Weak | Ryan Savitz CFO & CBO sell | $904k 20,000 shares | -100% | +201% from low0% from high | |
| 25Weak | Simrat Randhawa EVP, Head of R&D sell | $7.4M 196,538 shares | -215% | +139% from low-10% from high | |
| 28Weak | Ryan Savitz CFO & CBO sell | $700k 20,000 shares | -100% | +139% from low0% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 17, 2026 | EDWARD CARR Officer | 20,000 0.04% of outstanding | $2.0M | Sep 17, 2026 | none |
| Sep 1, 2026 | SIMRAT RANDHAWA Officer | 23,124 0.04% of outstanding | $2.4M | Sep 1, 2026 | none |
| Aug 10, 2026 | ANNE M MCGEORGE Director | 7,750 0.01% of outstanding | $844k | Aug 10, 2026 | none |
| Aug 10, 2026 | ADAM VENESS Officer | 16,167 0.03% of outstanding | $1.8M | Aug 10, 2026 | $2.8M |
| Aug 10, 2026 | Read Simon Officer | 5,550 0.01% of outstanding | $624k | Aug 10, 2026 | none |
| Aug 7, 2026 | MARINO GARCIA Officer | 126,000 0.23% of outstanding | $14M | Aug 7, 2026 | none |
| Aug 7, 2026 | ADAM VENESS Officer | 3,833 0.01% of outstanding | $421k | Aug 7, 2026 | $2.4M |
| Aug 7, 2026 | MARINO GARCIA Director, Officer | 40,000 0.07% of outstanding | $4.4M | Aug 7, 2026 | none |
| Jul 9, 2026 | RYAN SAVITZ Officer | 31,249 0.06% of outstanding | $3.1M | Jul 9, 2026 | none |
| Jun 17, 2026 | ADAM M VENESS Officer | 30,000 0.05% of outstanding | $2.4M | Jun 17, 2026 | none |
| Jun 1, 2026 | SIMRAT RANDHAWA Officer | 26,530 0.05% of outstanding | $2.5M | Jun 1, 2026 | $2.8M |
| Apr 9, 2026 | RYAN SAVITZ Officer | 8,224 0.02% of outstanding | $719k | Apr 9, 2026 | $9.5M |
| Mar 31, 2026 | PAULA C SOTEROPOULOS Director | 1,198 0.00% of outstanding | $95k | Mar 31, 2026 | $2.2M |
| Mar 31, 2026 | RYAN SAVITZ Officer | 114,367 0.26% of outstanding | $9.1M | Mar 31, 2026 | none |
| Mar 24, 2026 | PAULA C SOTEROPOULOS Director | 27,594 0.06% of outstanding | $2.2M | Mar 24, 2026 | none |
| Mar 12, 2026 | EDWARD CARR Officer | 43,682 0.10% of outstanding | $3.7M | Mar 12, 2026 | none |
| Mar 12, 2026 | SIMRAT RANDHAWA Officer | 33,830 0.08% of outstanding | $2.9M | Mar 12, 2026 | none |
| Mar 12, 2026 | MARINO GARCIA Director, Officer | 122,918 0.28% of outstanding | $11M | Mar 12, 2026 | none |
| Dec 4, 2025 | RYAN SAVITZ Officer | 20,000 0.05% of outstanding | $879k | Dec 4, 2025 | $700k |
| Nov 13, 2025 | SIMRAT RANDHAWA Officer | 196,538 0.46% of outstanding | $7.6M | Nov 13, 2025 | none |
| Sep 9, 2025 | RYAN SAVITZ Officer | 20,000 0.06% of outstanding | $636k | Sep 9, 2025 | none |
Transactions
The newest 50 of 178 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Edward Carr CHIEF ACCOUNTING OFFICER | MOption exercise Common Stock10b5-1 | +20,000 | $17.88 | $358k | 20,000 | 25 d ago |
| Sep 17, 2026 | Edward Carr CHIEF ACCOUNTING OFFICER | SOpen-market sale Common Stock10b5-1 | -7,928 | $100.43 | $796k | 12,072 | 25 d ago |
| Sep 17, 2026 | Edward Carr CHIEF ACCOUNTING OFFICER | SOpen-market sale Common Stock10b5-1 | -6,771 | $101.37 | $686k | 5,301 | 25 d ago |
| Sep 17, 2026 | Edward Carr CHIEF ACCOUNTING OFFICER | SOpen-market sale Common Stock10b5-1 | -3,501 | $102.39 | $358k | 1,800 | 25 d ago |
| Sep 17, 2026 | Edward Carr CHIEF ACCOUNTING OFFICER | SOpen-market sale Common Stock10b5-1 | -1,100 | $103.20 | $114k | 700 | 25 d ago |
| Sep 17, 2026 | Edward Carr CHIEF ACCOUNTING OFFICER | SOpen-market sale Common Stock10b5-1 | -700 | $104.39 | $73k | 0 | 25 d ago |
| Sep 17, 2026 | Edward Carr CHIEF ACCOUNTING OFFICER | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 43,818 | 25 d ago |
| Sep 1, 2026 | Simrat Randhawa EVP, Head of R&D | MOption exercise Common Stock10b5-1 | +7,500 | $17.88 | $134k | 11,500 | 40 d ago |
| Sep 1, 2026 | Simrat Randhawa EVP, Head of R&D | MOption exercise Common Stock10b5-1 | +6,249 | $21.77 | $136k | 17,749 | 40 d ago |
| Sep 1, 2026 | Simrat Randhawa EVP, Head of R&D | MOption exercise Common Stock10b5-1 | +9,375 | $22.07 | $207k | 27,124 | 40 d ago |
| Sep 1, 2026 | Simrat Randhawa EVP, Head of R&D | SOpen-market sale Common Stock10b5-1 | -2,600 | $105.19 | $273k | 24,524 | 40 d ago |
| Sep 1, 2026 | Simrat Randhawa EVP, Head of R&D | SOpen-market sale Common Stock10b5-1 | -7,215 | $106.25 | $767k | 17,309 | 40 d ago |
| Sep 1, 2026 | Simrat Randhawa EVP, Head of R&D | SOpen-market sale Common Stock10b5-1 | -13,309 | $106.74 | $1.4M | 4,000 | 40 d ago |
| Sep 1, 2026 | Simrat Randhawa EVP, Head of R&D | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 56,776 | 40 d ago |
| Sep 1, 2026 | Simrat Randhawa EVP, Head of R&D | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,249 | $0.00 | $0 | 41,676 | 40 d ago |
| Sep 1, 2026 | Simrat Randhawa EVP, Head of R&D | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,375 | $0.00 | $0 | 87,500 | 40 d ago |
| Aug 19, 2026 | Simon Read director | MOption exercise Common Stock10b5-1 | +2,778 | $18.36 | $51k | 2,778 | Aug 19, 2026 |
| Aug 19, 2026 | Simon Read director | SOpen-market sale Common Stock10b5-1 | -2,778 | $117.55 | $327k | 0 | Aug 19, 2026 |
| Aug 19, 2026 | Simon Read director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,778 | $0.00 | $0 | 19,445 | Aug 19, 2026 |
| Aug 13, 2026 | Adam M Veness SVP, General Counsel and Sec. | MOption exercise Common Stock | +15,000 | $18.17 | $273k | 15,000 | Aug 14, 2026 |
| Aug 13, 2026 | Adam M Veness SVP, General Counsel and Sec. | MOption exercise Stock Option (Right to Buy)derivative | -15,000 | $0.00 | $0 | 73,240 | Aug 14, 2026 |
| Aug 10, 2026 | Anne McGeorge director | MOption exercise Common Stock10b5-1 | +1,250 | $19.36 | $24k | 1,250 | Aug 11, 2026 |
| Aug 10, 2026 | Simon Read director | MOption exercise Common Stock10b5-1 | +2,777 | $18.36 | $51k | 2,777 | Aug 11, 2026 |
| Aug 7, 2026 | Adam M Veness SVP, General Counsel and Sec. | MOption exercise Common Stock10b5-1 | +3,833 | $17.88 | $69k | 3,833 | Aug 11, 2026 |
| Aug 10, 2026 | Anne McGeorge director | MOption exercise Common Stock10b5-1 | +6,500 | $11.20 | $73k | 7,750 | Aug 11, 2026 |
| Aug 7, 2026 | Adam M Veness SVP, General Counsel and Sec. | SOpen-market sale Common Stock10b5-1 | -3,217 | $110.61 | $356k | 616 | Aug 11, 2026 |
| Aug 10, 2026 | Simon Read director | SOpen-market sale Common Stock10b5-1 | -70 | $107.11 | $7,498 | 2,707 | Aug 11, 2026 |
| Aug 10, 2026 | Anne McGeorge director | SOpen-market sale Common Stock10b5-1 | -1,450 | $107.58 | $156k | 6,300 | Aug 11, 2026 |
| Aug 7, 2026 | Adam M Veness SVP, General Counsel and Sec. | SOpen-market sale Common Stock10b5-1 | -616 | $111.18 | $68k | 0 | Aug 11, 2026 |
| Aug 10, 2026 | Simon Read director | SOpen-market sale Common Stock10b5-1 | -737 | $108.17 | $80k | 1,970 | Aug 11, 2026 |
| Aug 10, 2026 | Anne McGeorge director | SOpen-market sale Common Stock10b5-1 | -2,800 | $108.38 | $303k | 3,500 | Aug 11, 2026 |
| Aug 10, 2026 | Simon Read director | SOpen-market sale Common Stock10b5-1 | -831 | $108.95 | $91k | 1,139 | Aug 11, 2026 |
| Aug 10, 2026 | Adam M Veness SVP, General Counsel and Sec. | MOption exercise Common Stock10b5-1 | +16,167 | $17.88 | $289k | 16,167 | Aug 11, 2026 |
| Aug 10, 2026 | Anne McGeorge director | SOpen-market sale Common Stock10b5-1 | -1,800 | $109.30 | $197k | 1,700 | Aug 11, 2026 |
| Aug 10, 2026 | Simon Read director | SOpen-market sale Common Stock10b5-1 | -272 | $109.96 | $30k | 867 | Aug 11, 2026 |
| Aug 10, 2026 | Adam M Veness SVP, General Counsel and Sec. | SOpen-market sale Common Stock10b5-1 | -16,167 | $110.38 | $1.8M | 0 | Aug 11, 2026 |
| Aug 10, 2026 | Anne McGeorge director | SOpen-market sale Common Stock10b5-1 | -1,000 | $110.64 | $111k | 700 | Aug 11, 2026 |
| Aug 7, 2026 | Adam M Veness SVP, General Counsel and Sec. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,833 | $0.00 | $0 | 76,167 | Aug 11, 2026 |
| Aug 10, 2026 | Simon Read director | SOpen-market sale Common Stock10b5-1 | -470 | $111.05 | $52k | 397 | Aug 11, 2026 |
| Aug 10, 2026 | Adam M Veness SVP, General Counsel and Sec. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -16,167 | $0.00 | $0 | 60,000 | Aug 11, 2026 |
| Aug 10, 2026 | Anne McGeorge director | SOpen-market sale Common Stock10b5-1 | -700 | $111.41 | $78k | 0 | Aug 11, 2026 |
| Aug 10, 2026 | Simon Read director | SOpen-market sale Common Stock10b5-1 | -397 | $111.77 | $44k | 0 | Aug 11, 2026 |
| Aug 10, 2026 | Anne McGeorge director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,250 | $0.00 | $0 | 0 | Aug 11, 2026 |
| Aug 10, 2026 | Simon Read director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,777 | $0.00 | $0 | 22,223 | Aug 11, 2026 |
| Aug 10, 2026 | Anne McGeorge director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,500 | $0.00 | $0 | 0 | Aug 11, 2026 |
| Aug 7, 2026 | Marino Garcia CEO AND PRESIDENT | MOption exercise Common Stock10b5-1 | +40,000 | $8.44 | $338k | 105,292 | Aug 7, 2026 |
| Aug 7, 2026 | Marino Garcia CEO AND PRESIDENT | MOption exercise Common Stock10b5-1 | +126,000 | $8.44 | $1.1M | 231,292 | Aug 7, 2026 |
| Aug 7, 2026 | Marino Garcia CEO AND PRESIDENT | SOpen-market sale Common Stock10b5-1 | -10,384 | $107.49 | $1.1M | 220,908 | Aug 7, 2026 |
| Aug 7, 2026 | Marino Garcia CEO AND PRESIDENT | SOpen-market sale Common Stock10b5-1 | -23,907 | $108.05 | $2.6M | 197,001 | Aug 7, 2026 |
| Aug 7, 2026 | Marino Garcia CEO AND PRESIDENT | SOpen-market sale Common Stock10b5-1 | -2,373 | $109.10 | $259k | 194,628 | Aug 7, 2026 |
50 of 178 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Edward CarrCHIEF ACCOUNTING OFFICER
- Marino GarciaCEO AND PRESIDENT
- Anne McGeorgedirector
- Simrat RandhawaEVP, Head of R&D
- Simon Readdirector
- Ryan SavitzEVP, CFO & CBO
- Paula Soteropoulosdirector
- Adam M VenessSVP, General Counsel and Sec.
Questions about DNTH
Answered from the filings on this page, as of the latest one.
Are insiders buying DNTH?
As of Sep 18, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 7 open-market sells worth $26M by 6 insiders at Dianthus Therapeutics, Inc. /DE/ in the last 90 days, net -$26M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade DNTH on the open market?
Edward Carr (CHIEF ACCOUNTING OFFICER) sold $2.0M of DNTH on Sep 17, 2026 and filed the Form 4 on Sep 18, 2026. InsiderTell scored 25 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at Dianthus Therapeutics, Inc. /DE/?
8 people have filed a Form 4 at Dianthus Therapeutics, Inc. /DE/, among them Edward Carr (CHIEF ACCOUNTING OFFICER), Marino Garcia (CEO AND PRESIDENT), Anne McGeorge (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.